Literature DB >> 21992778

Somatic afferent modulation of thoracic (T9-T10) spinal neurons receiving gastric mechanical input in rats.

Chao Qin1, Jiande D Z Chen, Jing Zhang, Robert D Foreman.   

Abstract

OBJECTIVES: The aim was to determine whether somatic afferent fiber stimulation influences thoracic spinal neuronal activity responding to gastric distensions.
MATERIALS AND METHODS: Extracellular potentials of single T9-T10 spinal neurons were recorded in anesthetized male rats. Ipsilateral median and peroneal nerve afferent stimulation (MNAS, PNAS) was delivered by electrodes. Inflation of a latex balloon was used to produce gastric distension.
RESULTS: MNAS and PNAS (1.5 mA, 50 Hz, 10 sec) altered activity of 63% and 66% of the spinal neurons excited or inhibited by gastric distension, respectively. MNAS more frequently reduced spinal neuronal activity with excitatory responses to gastric distension than did PNAS (p < 0.05). PNAS more likely increased neuronal activity with low-threshold excitatory responses to gastric distension than MNAS (p < 0.05).
CONCLUSIONS: Peripheral somatic afferent information utilizes central pathways to modulate gastric afferent processing in T9-T10 spinal neurons. Thus, somatic afferent stimulation might be used to treat gastric pain and/or hypersensitivity.
© 2009 International Neuromodulation Society.

Entities:  

Year:  2009        PMID: 21992778     DOI: 10.1111/j.1525-1403.2009.00258.x

Source DB:  PubMed          Journal:  Neuromodulation        ISSN: 1094-7159


  2 in total

1.  Chronic Electrical Stimulation at Acupoints Reduces Body Weight and Improves Blood Glucose in Obese Rats via Autonomic Pathway.

Authors:  Jiemin Liu; Haifeng Jin; Robert D Foreman; Yong Lei; Xiaohong Xu; Shiying Li; Jieyun Yin; Jiande D Z Chen
Journal:  Obes Surg       Date:  2015-07       Impact factor: 4.129

2.  Effects of Transcutaneous Electrical Acustimulation on Refractory Gastroesophageal Reflux Disease.

Authors:  Li-Na Meng; Shanshan Chen; Jiande D Z Chen; Hai-Feng Jin; Bin Lu
Journal:  Evid Based Complement Alternat Med       Date:  2016-08-28       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.